Market Overview

UPDATE: Piper Jaffray Reiterates Sarepta Therapeutics at Buy on Positive Eteplirsen Data

Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval
Mid-Day Market Update: Starwood Hotels Jumps Following CEO Resignation; CoStar Group Shares Slide
Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on Q4 2014 Results -- Earnings Call Transcript (Seeking Alpha)

Piper Jaffray maintained its Buy rating and $38 price target on Sarepta Therapeutics (NASDAQ: SRPT) following data showing consistent benefit for the company's treatment.

Piper Jaffray commented, "This morning Sarepta announced maintenance of clinical benefit up to 62 weeks for eteplirsen treated patients from the Phase IIb extension study 202. Data comparing the eteplirsen and placebo/ treatment delayed groups through week 62 showed a 61.9 m (p=0.007) statistically significant difference. Sarepta is preparing briefing documents to submit to the FDA for an end-of-Phase II meeting, likely to be held in 1Q:13. The company will ask the agency if eteplirsen is appropriate for accelerated approval. Regardless, Sarepta will conduct a confirmatory study to begin in 2014. We continue to believe eteplirsen shows significant, meaningful clinical benefit and reiterate our Overweight rating and $38 price target."

Sarepta Therapeutics closed at $27.48 on Thursday.

Latest Ratings for SRPT

Feb 2015Cowen & CompanyDowngradesOutperformMarket Perform
Feb 2015Bank of AmericaUpgradesBuy
Jan 2015WedbushInitiates Coverage onNeutral

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (SRPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters